Christina Bradley

Array ( [id] => 17702705 [patent_doc_number] => 20220202711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins [patent_app_type] => utility [patent_app_number] => 17/540448 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17540448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893784 [patent_doc_number] => 20240009269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => MEMBRANE-ACTIVE PEPTIDES AND METHODS FOR REVERSIBLE BLOOD- BRAIN BARRIER OPENING [patent_app_type] => utility [patent_app_number] => 18/253084 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842677 [patent_doc_number] => 20230405081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 18/252438 [patent_app_country] => US [patent_app_date] => 2021-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842677 [patent_doc_number] => 20230405081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 18/252438 [patent_app_country] => US [patent_app_date] => 2021-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842559 [patent_doc_number] => 20230404963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/036565 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842559 [patent_doc_number] => 20230404963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/036565 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844479 [patent_doc_number] => 20230406883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 18/252056 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428375 [patent_doc_number] => 20220056083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => STREPTAVIDIN MUTEINS AND METHODS OF USING THEM [patent_app_type] => utility [patent_app_number] => 17/521146 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17521146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817505 [patent_doc_number] => 20230391845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => GLP-1, GIP AND GLUCAGON RECEPTOR TRIPLE AGONISTS [patent_app_type] => utility [patent_app_number] => 18/033572 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19299967 [patent_doc_number] => 20240228536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => PEPTIDES FOR USE IN SKIN AND HAIR PIGMENTATION [patent_app_type] => utility [patent_app_number] => 18/250448 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830852 [patent_doc_number] => 20230399377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => INHIBITORS OF ANGIOGENIC FACTORS [patent_app_type] => utility [patent_app_number] => 18/250977 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685909 [patent_doc_number] => 20220193201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => GLP-1R AGONIST REDUCES RETINAL INFLAMMATION AND NEURON DEATH SECONDARY TO OCULAR HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/504500 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685909 [patent_doc_number] => 20220193201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => GLP-1R AGONIST REDUCES RETINAL INFLAMMATION AND NEURON DEATH SECONDARY TO OCULAR HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/504500 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655416 [patent_doc_number] => 20220175881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => METHOD OF TREATING CONDITIONS OF THE EYE WITH AN ANTI-VEGF DARPIN [patent_app_type] => utility [patent_app_number] => 17/500315 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503494 [patent_doc_number] => 20220096596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHOD OF TREATING AMD IN PATIENTS REFRACTORY TO ANTI-VEGF THERAPY [patent_app_type] => utility [patent_app_number] => 17/500307 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817489 [patent_doc_number] => 20230391829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => AAV8 AFFINITY AGENTS [patent_app_type] => utility [patent_app_number] => 18/031833 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817489 [patent_doc_number] => 20230391829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => AAV8 AFFINITY AGENTS [patent_app_type] => utility [patent_app_number] => 18/031833 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505151 [patent_doc_number] => 20220098253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => LIPOCALIN MUTEINS WITH BINDING AFFINITY FOR LAG-3 [patent_app_type] => utility [patent_app_number] => 17/499640 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17499640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901406 [patent_doc_number] => 20240016891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROMUSCULAR DISEASES COMPRISING CDO PROTEIN OR GENE ENCODING SAME [patent_app_type] => utility [patent_app_number] => 18/250629 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786083 [patent_doc_number] => 20230374070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => AMYLOID-beta AGGREGATION INHIBITOR, PHARMACEUTICAL COMPOSITION FORAMYLOID-beta AGGREGATION DISEASE, AND USE APPLICATION OF SAME [patent_app_type] => utility [patent_app_number] => 18/247584 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247584 [rel_patent_id] =>[rel_patent_doc_number] =>)